ScreenerHero

IRDOpus Genetics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · opusgtx.com
4.050USD-0.49%Mkt Cap: 336.94M $P/E: —

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap336.94M $
Enterprise Value290.16M $
Revenue (TTM)9.86M $
Gross Profit-28.77M $
Net Income (TTM)-49.59M $
Revenue/Share0.1180 USD
Last Price4.050 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.81
PEG—
EV/EBITDA-5.74
EV/Revenue29.44
P/S34.78
P/B-26.24
EPS (TTM)-1.30
EPS (Forward)-0.71
52W Range
1.10063% of range5.810
52W High5.810 USD
52W Low1.100 USD
Profitability
Gross Margin-291.85%
Oper. Margin-2182.78%
EBITDA Margin0.00%
Profit Margin-349.33%
ROE-323.11%
ROA-98.70%
Growth
Revenue Growth-73.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.25M $
CapEx (TTM)—
FCF Margin-391.19%
FCF Yield-11.44%
Net Debt-52.61M $
Net Debt/EBITDA1.04
Balance Sheet
Debt/Equity0.07
Current Ratio12.19
Quick Ratio11.87
Book Value/Sh-0.1570 USD
Cash/Share1.068 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 6, 2020
Splits
Last Split1:4
Split DateNov 6, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.61 USD
Upside (mean)+162.0%
Target Range8.000 USD – 16.00 USD
$8.000+162.0% to mean$16.00
# Analysts18
Ownership
Shares Out.83.20M
Float65.21M
Insiders10.94%
Institutions69.25%
Short Interest
Short Ratio12.5d
Short % Float13.81%
Short % Out.13.13%
Shares Short10.85M
Short (prev mo.)8.23M
Technical
SMA 503.743 (+8.2%)
SMA 2003.581 (+13.1%)
Beta0.58
S&P 52W Chg18.16%
Avg Vol (30d)785.80K
Avg Vol (10d)702.40K
Technical Indicators
RSI (14)60.7
MACD0.0563
MACD Signal-0.0018
MACD Hist.+0.0580
BB Upper4.198 USD
BB Middle3.635 USD
BB Lower3.071 USD
BB Width30.99%
ATR (14)0.2579 USD
Vol Ratio (20d)1.39x